Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — FY2025 Earnings Presentation
23 slides from Burjeel's earnings presentation, March 2026
Slide 1: Q4 & FY 2025 Financial Results
Q4 & FY 2025 Financial Results Earnings Presentation March 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Key Highlights
Key Highlights Leading Super-Specialty Healthcare Provider in the GCC
Slide 4: 2025: Built on Strength – Guidance Delivered
2025: Built on Strength – Guidance Delivered Full-Year Highlights Transition from Build-Out to Performance 2025 YoY Patients 7.0m +8% Revenue AED 5.5bn +10% 2024 2025 Mid-Term Investment Execution & Disciplined Phase Stabilization Value Creation EBITDA AED 1.1bn +20% Net Profit AED 503m +39% Rapid n
Slide 5: 2025: A Momentous Year – Platform Expansion & Breakthroughs in Medical Excellence
2025: A Momentous Year – Platform Expansion & Breakthroughs in Medical Excellence Expanding Advancing Scaling Embedding Integrated Network Complex Care Clinical Excellence Medical Innovation Hospitals & Specialized GCC’s First & Only Day Care Centers Osseointegration 31 UAE’s Youngest Organ Pediatri
Slide 6: Integrated End-to-End Complex Care
Oncology Multi-Organ Transplant Kidney & Liver Living & Deceased Immunotherapy Palliative Care Transplants Donation ABO-Incompatible Precision Diagnostics Nuclear Medicine Pediatric Transplants Cases Medical & Radiation Robotic Transplant Surgical Oncology Oncology Transplant Surgery Immunology Bone
Slide 7: Digital & AI Platform: Driving Structural Efficiency, Margin Expansion & Care Excellence
Digital & AI Platform: Driving Structural Efficiency, Margin Expansion & Care Excellence Digital Core Infrastructure • Unified EMR Embedded AI Across the Care Continuum • Real-time KPIs • Standardized workflows Oracle Command Center IP/OP AI & Clinical Intelligence AI-driven clinical analytics & dec
Slide 8: Expanding Reach, Enhancing Care: Disciplined Execution Across Growth Pipeline
Expanding Reach, Enhancing Care: Disciplined Execution Across Growth Pipeline 2026 Expected Impact 2027- 2028 at Maturity 1 1 1 1 AED 1.5 bn Revenue Hospital Fertility Clinic Hospital Fertility Clinic Mid-20s 1 3 1 3 EBITDA Margin Day Surgery Medical Day Surgery Medical Centers Center (KSA) Centers
Slide 9: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in the GCC
Slide 10: Accelerating Market Penetration Driving Record Quarterly Patient Volumes
Accelerating Market Penetration Driving Record Quarterly Patient Volumes Group Outpatient Footfall, k Group Inpatient Footfall, k % OP utilisation % bed occupancy • Total patient footfall grew 8.4% YoY to over • Inpatient footfall increased 11.7% in FY’25 7 million in FY’25 and accelerated to and 9.
Slide 11: Hospitals Powering Profit Growth While Medical Centers Scale Rapidly
Hospitals Powering Profit Growth While Medical Centers Scale Rapidly Group Revenue, AED m Group EBITDA, AED m YoY EBITDA margin YoY 1,388 • Total revenue increased 6.3% in Q4’25, • Group EBITDA grew 35.4% YoY in Q4’25, driven by new facility ramp-up and a with margin up by 4.4pp. +6.3% rebound in pa
Slide 12: Burjeel Medical City Scaling Volumes With Delivering Strong Margin Expansion
Burjeel Medical City Scaling Volumes With Delivering Strong Margin Expansion Patients, k Revenue, AED m1 EBITDA, AED m1 % bed occupancy % EBITDA margin 68% 60% 62% 61% 15.3% 18.3% 15.9% 18.7% +18.3% +7.1% +26.1% 638 1,290 241 1,205 539 192 +15.6% (3.3%) +15.5% 175 326 315 58 151 50 Q4'24 Q4'25 FY'24
Slide 13: Margin Normalization Progressing Through Asset Maturity & Cost Discipline
Margin Normalization Progressing Through Asset Maturity & Cost Discipline Group OPEX Breakdown, % of Revenue Group EBITDA Analysis, AED m % EBITDA margin 84.4% 82.0% 81.4% 79.4% 15.9% 20.3% 13.4% 11.5% 12.7% 11.4% +50 (41) 2.2% 2.1% 3.3% (7) 2.5% +83 (2) (9) 282 25.0% 24.9% 23.0% 19.9% 208 43.9% 44.
Slide 14: Robust Free Cash Flow Generation Reflecting Strong EBITDA Growth & Disciplined Investment
Robust Free Cash Flow Generation Reflecting Strong EBITDA Growth & Disciplined Investment Net Cash from Operating Activities, AED m Total Investments, AED m % FCF conversion1 Growth CAPEX Maintenance CAPEX Acquisitions & Investments in Associates 48% +81 41% (262) 716 +142 131 500 (37) (19) (3) 402
Slide 15: AI-Enabled Claims Management & Insurance Alignment Driving Working Capital Normalization
AI-Enabled Claims Management & Insurance Alignment Driving Working Capital Normalization AI-Driven Centralized Claims Management Claims Submission Process (Integrated with Oracle) 100+ CDI professionals Medical Coding Training & Education 1000+ Initial Submission Resubmission Payment Medical Claim P
Slide 16: Well-Capitalized Balance Sheet Supporting Future Growth & Value Creation
Well-Capitalized Balance Sheet Supporting Future Growth & Value Creation AED m 31 December 2025 31 December 2024 Debt Maturity as of 31 December 2025 Bank balances and cash 281 238 Interest-bearing loans and borrowings 1,918 1,208 526 Bank overdraft — — 414 346 340 Bank debt1 1,918 1,208 Net debt 1,
Slide 17: Strong Profitability Momentum With Continued Commitment to Dividends
Strong Profitability Momentum With Continued Commitment to Dividends Net Profit Evolution, AED m Commentary % net profit margin • Full-year net profit increased 39.5% YoY to AED 503 million, with net margin improving to 7.0% 9.0% 11.9% 7.2% 9.2% 4.1% 10.1% 9.2%, driven by strong operating leverage,
Slide 18: Strategic Growth Pillars
Strategic Growth Pillars Ramp-up of Growth Assets Increasing Patient Yield Operational Excellence Geographic Expansion Group Revenue Patient Yield Group EBITDA Margin Healthcare Assets Low- Single 5.5bn Double Mid-Term Mid-Term Mid-Term ‘25 Digit CAGR Target ‘25 752 Digit Target ‘25 20% Low-20s Targ
Slide 19: Appendix
Appendix Leading Super-Specialty Healthcare Provider in the GCC
Slide 20: Q4’25 & FY’25 Financial Summary
Q4’25 & FY’25 Financial Summary Group Group Income Statement Summary Financial Performance by Segment AED m Q4’25 Q4’24 FY’25 FY’24 AED m Q4’25 Q4’24 2025 2024 Revenue 1,388 1,305 5,486 5,010 Revenue 1,388 1,305 5,486 5,010 Inventories consumed (276) (327) (1,261) (1,246) Hospitals2 1,222 1,181 4,84
Slide 21: FY’25 Financial Summary
FY’25 Financial Summary Balance Sheet Summary AED m 31 Dec 2025 31 Dec 2024 Change AED m 31 Dec 2025 31 Dec 2024 Change Shareholders' equity Non-current assets Share capital 521 521 – Property and equipment 2,127 1,932 +195 Shareholder’s contribution 4 4 – Intangible assets 20 16 +4 Other reserves 3
Slide 22: FY’25 Financial Summary
FY’25 Financial Summary Cash Flow Summary AED, m FY’25 FY’24 Change, % Operating activities Net Profit for the Period Before Tax 541 399 +35.5% Non-cash adjustments 711 630 +12.9% Working capital adjustments (677) (415) +63.0% Other (173) (114) +51.5% Net Cash, Operating activities 402 500 (19.5%) I
Slide 23: IR Contacts
IR Contacts March 2026 Sergei Levitskii Director of Investor Relations Investor Feedback Hotline sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 Engaging openly with our investors and analysts is a cornerstone of our approach. We’ve partnered with Closir to make sharing your feedback quick a